Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia

  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
  • Menacho-Márquez, Mauricio
  • Fernández-Pisonero, Isabel
  • Abad, Antonio
  • Camós, Mireia|||0000-0003-3658-7942
  • Toribio, María L.|||0000-0002-8637-0373
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Bustelo, Xosé R.
Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are deemed as potential therapeutic targets owing to their protumorigenic functions. However, the understanding of the spectrum of their pathobiological roles in tumors is still very limited. We report here that the GEF Vav1 unexpectedly possesses tumor-suppressor functions in immature T cells. This function entails the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is essential for the pathogenesis of human T-ALL of the TLX + clinical subtype, further underscoring the suppressor role of this pathway. Robles-Valero et al. find that Vav1 facilitates binding of Cbl-b to the intracellular domain of Notch1 (ICN1) and promotes ICN1 degradation. Loss of Vav1 induces T cell acute lymphoblastic leukemia (T-ALL) by increasing ICN1 signaling, and TLX inhibits Vav1 expression to stimulate ICN1 signaling in TLX + T-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma

  • Gallardo, Fernando|||0000-0002-8996-3828
  • Bertran, Joan
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • González, Jéssica
  • Menéndez, Silvia
  • Sánchez, Ignacio
  • Colomo, Luis|||0000-0001-5236-5085
  • Iglesias, Mar|||0000-0002-2274-4671
  • Garrido, Marta
  • Santamaría-Babí, Luis Francisco
  • Torres, Ferran|||0000-0002-7355-7913
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and β-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Blocking PP1 activity, both pharmacologically and genetically, resulted in TAK1 hyperphosphorylation at residues T344, S389, T444, and T511, which have functional impact on canonical NF-κB signaling. Inhibition of TAK1 precluded NF-κB and β-catenin signaling and induced apoptosis of CTCL cell lines and primary Sézary syndrome cells both in vitro and in vivo. Detection of phosphorylated TAK1 at T444 and T344 is associated with the presence of lymphoma in a set of 60 primary human samples correlating with NF-κB and β-catenin activation. These results identified TAK1 as a potential biomarker and therapeutic target for CTCL therapy.